RT Journal Article
T1 Role of assessing liver fibrosis in management of chronic hepatitis C virus infection.
A1 Carmona, I
A1 Cordero, P
A1 Ampuero, J
A1 Rojas, A
A1 Romero-Gómez, M
K1 Direct-acting antiviral
K1 Hepatitis C
K1 Liver biopsy
K1 Non-invasive markers
K1 Pegylated interferon
AB Fibrosis progression is common in hepatitis C. Both host and viral factors influence its natural history. Liver fibrosis is a key predictive factor for advanced disease including endpoints such as liver failure, cirrhosis and hepatocellular carcinoma (HCC). METAVIR fibrosis stages F3-F4 have been considered as the threshold for antiviral therapy. However, this aspect is controversial after the advent of new direct-acting antivirals (DAAs) because they show an excellent efficacy and safety profile. Moreover, in the DAA era, fibrosis stage seems not to be a predictive factor of a sustained virological response (SVR). Viral eradication decreases liver damage by improving the inflammation, as well as by regressing fibrosis irrespective of the treatment regimen. Non-invasive methods are useful in the assessment of liver fibrosis, replacing liver biopsy in clinical practice; but their usefulness for monitoring fibrosis after SVR needs to be demonstrated. Fibrosis regression has been demonstrated after the eradication of hepatitis C virus infection and is associated with a lower risk of hepatic cirrhosis and liver cancer. However, patients showing advanced fibrosis and cirrhosis must be followed-up after SVR, as risks of portal hypertension and HCC remain.
YR 2016
FD 2016-09-24
LK http://hdl.handle.net/10668/10478
UL http://hdl.handle.net/10668/10478
LA en
DS RISalud
RD Apr 19, 2025